{"entity":"astrazeneca","id":"ent_astrazeneca","name":"AstraZeneca","from":"2025-11-08","to":"2026-11-08","page":"https://asof.is/record/astrazeneca/diff?from=2025-11-08&to=2026-11-08","summary":"Between 2025-11-08 and 2026-11-08, AstraZeneca's record changed in 5 facts: 5 replaced (net income $7.04 billion → $10.23 billion; operating income $10 billion → $13.74 billion; revenue $54.07 billion → $58.74 billion and 2 more); 8 unchanged.","counts":{"changed":5,"added":0,"ended":0,"replaced":5,"unchanged":8,"skipped_posts":{"from":0,"to":0}},"by_predicate":[{"predicate":"net_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"operating_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"revenue","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"total_assets","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"total_equity","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"cik","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"fiscal_year_end","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"headquarters","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"listed_on","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"registrant_name","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"sic_industry","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"state_of_incorporation","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"ticker","added":0,"ended":0,"replaced":0,"unchanged":1}],"added":[],"ended":[],"replaced":[{"predicate":"net_income","from":{"id":"clm_DCF412B5DDDA","predicate":"net_income","value":"7,041,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 7,041,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_DCF412B5DDDA, https://asof.is/claim/clm_DCF412B5DDDA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_DCF412B5DDDA","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7F0BFE9EB1CD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2024, filed 2025-02-18"}},"to":{"id":"clm_7F0BFE9EB1CD","predicate":"net_income","value":"10,233,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 10,233,000,000 United States dollar\", as of 2025-12-31. Claim clm_7F0BFE9EB1CD, https://asof.is/claim/clm_7F0BFE9EB1CD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm.","url":"https://asof.is/claim/clm_7F0BFE9EB1CD","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2025, filed 2026-02-24"}}},{"predicate":"operating_income","from":{"id":"clm_3994638C1B14","predicate":"operating_income","value":"10,003,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 10,003,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_3994638C1B14, https://asof.is/claim/clm_3994638C1B14, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_3994638C1B14","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_763AA2791DE9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2024, filed 2025-02-18"}},"to":{"id":"clm_763AA2791DE9","predicate":"operating_income","value":"13,743,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 13,743,000,000 United States dollar\", as of 2025-12-31. Claim clm_763AA2791DE9, https://asof.is/claim/clm_763AA2791DE9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm.","url":"https://asof.is/claim/clm_763AA2791DE9","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2025, filed 2026-02-24"}}},{"predicate":"revenue","from":{"id":"clm_5BDDB85A5719","predicate":"revenue","value":"54,073,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 54,073,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_5BDDB85A5719, https://asof.is/claim/clm_5BDDB85A5719, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_5BDDB85A5719","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_75285D1846DF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2024, filed 2025-02-18"}},"to":{"id":"clm_75285D1846DF","predicate":"revenue","value":"58,739,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 58,739,000,000 United States dollar\", as of 2025-12-31. Claim clm_75285D1846DF, https://asof.is/claim/clm_75285D1846DF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm.","url":"https://asof.is/claim/clm_75285D1846DF","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2025, filed 2026-02-24"}}},{"predicate":"total_assets","from":{"id":"clm_F05CE2B1D291","predicate":"total_assets","value":"104,035,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 104,035,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_F05CE2B1D291, https://asof.is/claim/clm_F05CE2B1D291, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_F05CE2B1D291","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B12E0C1D9275","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2024, filed 2025-02-18"}},"to":{"id":"clm_B12E0C1D9275","predicate":"total_assets","value":"114,074,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 114,074,000,000 United States dollar\", as of 2025-12-31. Claim clm_B12E0C1D9275, https://asof.is/claim/clm_B12E0C1D9275, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm.","url":"https://asof.is/claim/clm_B12E0C1D9275","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2025, filed 2026-02-24"}}},{"predicate":"total_equity","from":{"id":"clm_702A322E3B09","predicate":"total_equity","value":"40,871,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 40,871,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_702A322E3B09, https://asof.is/claim/clm_702A322E3B09, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_702A322E3B09","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_327B10FB292B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2024, filed 2025-02-18"}},"to":{"id":"clm_327B10FB292B","predicate":"total_equity","value":"48,719,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 48,719,000,000 United States dollar\", as of 2025-12-31. Claim clm_327B10FB292B, https://asof.is/claim/clm_327B10FB292B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm.","url":"https://asof.is/claim/clm_327B10FB292B","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2025, filed 2026-02-24"}}}],"rule":"Two states compared by claim id: in both, unchanged; only on to, added; only on from, ended. An ended and an added claim on one predicate are a replacement when the ended one points to the added (superseded_by), or the predicate has exactly one of each and the added begins the day the ended ends. Added rows are labelled for to, ended rows for from. Posts and Hugging Face repos are counted in skipped_posts, not listed.","legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}